Safety Alerts & Recalls
What does this mean?
This recall for Apidra SoloStar [insulin glulisine (rDNA origin) injection] from Sanofi-Aventis was issued at a warehouse and pharmacy level only. The FDA and the company involved have determined that any recalled product that may have been dispensed to patients does not pose a significant health risk. If you use Apidra SoloStar [insulin glulisine (rDNA origin) injection] and are concerned, you should speak to your pharmacist, or the healthcare professional (doctor, nurse) managing your diabetes.
Sanofi-Aventis Recalls Single Lot of Apidra SoloStar
Sanofi-Aventis has recalled a single lot of Apidra SoloStar [insulin glulisine (rDNA origin) injection], 100 units/mL (U-100), packaged in boxes of five 3 mL prefilled pens. Lot number 0F151A has been recalled because this lot may not meet the standard of sterility.
Apidra SoloStar contains the active ingredient insulin glulisine (rDNA origin) and is commonly used in the treatment of diabetes. This recall alert only applies to the single lot of Apidra SoloStar. No other Apidra products were involved in this recall.
To view the FDA notice about this recall, please visit: more information here